Dengue Zika Chikungunya Cuba
Recent Comments

    Biotech Mission to Cuba
    BETC director Kamal Rashid hopes to develop collaborations in
    March 20, 2017

    As the 1950s vintage cars course through city streets seemingly frozen
    in time, a vibrant biopharmaceutical sector flourishes in Cuba,
    supplying most of the country’s essential medicines and exporting
    life-saving vaccines to developing countries.

    “It was not what I expected to find,” says Kamal Rashid, PhD, director
    of WPI’s Biomanufacturing Education and Training Center, who was part of
    a Massachusetts Biotechnology Council (MassBio) delegation that
    traveled to Cuba in February.

    The MassBio group, which also included research and business development
    leaders from several companies, Harvard University, Massachusetts
    College of Pharmacy and Health Sciences, and Massachusetts Biomedical
    Initiatives, joined Bay State congressmen Jim McGovern of Worcester and
    Seth Moulton of Salem for the three-day mission.

    “With the new openness between the United States and Cuba, we want to
    seize the opportunity to explore mutually beneficial collaborations in
    both biologics research and biomanufacturing,” Rashid says.
    “Massachusetts is a world leader in biopharmaceutical development and
    manufacturing, so it makes sense for both sides to begin building
    relationships. And having the two Congressmen with us was very important
    in terms of access and respect from the Cuban leadership. Their presence
    elevated our mission.”

    In addition to his work at WPI, Utah State, and Penn State, Rashid has
    led biotechnology research, education, and biomanufacturing workforce
    training programs in 15 countries and territories, including multiple
    projects in the Dominican Republic and Puerto Rico. Based on his
    experience, Rashid says Cuba is “the clear biotech leader in Latin America.”

    “I was quite impressed with the scale of their capabilities and their
    research in several programs,” he says. “The Cuban government made an
    early commitment to investing in biotechnology in the 1980s and they
    have followed through, in spite of a very difficult economy and the
    impact of the U.S. trade embargo.”

    BioCubaFarma is the government run umbrella organization for the
    industry. It has 31 affiliated entities and 62 production centers. It
    has a staff of over 22,000 people and manufactures 525 of the 849 drugs
    in Cuba’s catalog of essential medicines.

    Rashid and the delegation met with BioCubaFarma leaders and visited
    research scientists at Cuba’s Center for Genetic Engineering and
    Biotechnology. That center has developed 21 products, including cancer
    immunotherapies, a hepatitis B vaccine, and therapies for macular

    Rashid and colleagues also met with scientists and leaders at Cuba’s
    Institute of Tropical Medicine “Pedro Kouri” (named for its founder),
    which has operated continuously since 1937. The institute houses a World
    Health Organization (WHO) and Pan-American Health Organization (PAHO)
    collaborative center for the study of viral diseases, with a current
    focus on dengue fever, Zika, and measles.

    Rashid says he saw strengths in vaccines, cancer therapies. and
    medicinal plants that U.S.-based companies could help advance to larger
    scale clinical trials. What the Cubans need are partnerships and access
    to U.S./Western research funding, technology, and investments in
    production capabilities, he notes.

    “It was a first step and I believe we started some important
    conversations,” Rashid says. “The next step is for a group of Cuban
    scientists and biotech leaders to travel here to Massachusetts. I hope
    that will happen within the year.”

    – By Michael Cohen

    Source: Biotech Mission to Cuba | News | WPI –

    Leave a Reply

    Your email address will not be published. Required fields are marked *